The Cancer Drug That Fights Cortisol to Kill Tumors
The FDA just approved a drug that fights cancer by blocking your own stress hormone. Lifyorli targets cortisol-driven chemo resistance in platinum-resistant ovarian cancer, and the survival data from the ROSELLA trial is turning heads.
Your body's stress hormone might be protecting your cancer. That's the unsettling idea behind Lifyorli (relacorilant), a new drug the FDA just approved for one of the hardest-to-treat cancers in oncology. And the clinical data suggests blocking that hormone could give patients months of extra life.
On March 25, the FDA greenlit Lifyorli in combination with nab-paclitaxel (a chemo drug) for adults with platinum-resistant ovarian cancer who've been through one to three prior treatments, including at least one round of bevacizumab. This is Corcept Therapeutics' big moment, and it arrived roughly 3.5 months ahead of the FDA's target decision date.
That early approval isn't just a nice headline for Corcept's investor deck. For patients running out of options, every month matters.
The Worst Kind of Recurring Nightmare
Ovarian cancer is already brutal. But when it becomes "platinum-resistant," meaning the cancer stops responding to platinum-based chemo, the playbook gets painfully thin. Standard options include single-agent chemotherapy drugs like topotecan or pegylated liposomal doxorubicin. Average survival hovers around 13 months. Response rates are low, and side effects are high.
Think of it like antibiotics. When bacteria become resistant, you need a fundamentally different approach. The same logic applies here: once platinum stops working, you can't just try harder with the same class of drug.
That's what makes Lifyorli genuinely interesting. It doesn't try to be a better chemotherapy. It attacks the problem from a completely different angle.
Your Stress Hormone Is a Double Agent
Cortisol is the body's main stress hormone. It helps you wake up in the morning, respond to threats, and regulate inflammation. Useful stuff. But inside a tumor, cortisol plays a darker role.
When cortisol binds to glucocorticoid receptors (GR) on cancer cells, it flips on genes that help those cells survive chemotherapy. It's like a bouncer letting cancer cells skip the line past chemo's bouncers. The tumor essentially hijacks your own stress response to shield itself from treatment.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Relacorilant is a selective glucocorticoid receptor modulator. In plain English: it blocks cortisol from activating those protective pathways in cancer cells, without messing with other hormone receptors like progesterone. That selectivity matters because it means fewer off-target side effects compared to older, less precise cortisol blockers like mifepristone.
The combo logic is straightforward. Nab-paclitaxel does the killing; relacorilant strips away cortisol's shield so the chemo can actually reach the target.
The Trial That Got It Done
The approval rests on the ROSELLA trial, a Phase 3 study that enrolled 381 patients across the U.S., Europe, South Korea, Brazil, Argentina, Canada, and Australia. Patients were randomized 1:1 to get either relacorilant plus nab-paclitaxel or nab-paclitaxel alone. No biomarker selection was required, meaning any patient who met the criteria could enroll. That's a big deal for a cancer where precision medicine options are scarce.
ROSELLA hit both of its primary endpoints.
Progression-free survival (the time before the cancer starts growing again) came in at 6.5 months for the combo versus 5.5 months for chemo alone. That translates to a 27% reduction in the risk of disease progression or death (HR 0.70, p=0.0076).
But the headline number is overall survival. Patients on the relacorilant combo lived a median of 16 months, compared to 11.9 months on chemo alone. That's a 35% reduction in the risk of death (HR 0.65, p=0.0004). In a disease where every additional month is hard-won, four extra months of median survival is significant.
Critically, adding relacorilant didn't pile on extra toxicity. Adverse events were comparable in type, frequency, and severity between both arms. The most common issues were fatigue, nausea, diarrhea, rash, and decreased appetite, along with lab findings like reduced blood cell counts.
A Clever Dosing Trick
Relacorilant is an oral pill, which already makes it more convenient than many oncology drugs. But the dosing schedule is particularly smart: patients take it the day before, the day of, and the day after each nab-paclitaxel infusion. This targeted dosing window means cortisol's protective effect gets blocked precisely when the chemo is circulating, rather than requiring constant daily dosing.
One important contraindication: patients who need corticosteroids for life-saving conditions (think severe asthma or organ transplant patients) can't take Lifyorli, since blocking cortisol's effects could be dangerous for them. Warnings also include risks of neutropenia (low white blood cell counts), adrenal insufficiency, and embryo-fetal toxicity.
The Price Tag and the Pipeline
Lifyorli launched shortly after approval at $37,900 per 28-day cycle, with patient assistance programs available. That's not cheap, but it's within the range of specialty oncology pricing, and Corcept says it expects broad insurance coverage.
For Corcept Therapeutics, this is a transformative moment. The company has historically been a one-drug shop built around Korlym (mifepristone) for Cushing's syndrome. A second commercial product, especially one in oncology, diversifies the business significantly.
That growth potential isn't just about ovarian cancer. The cortisol-resistance mechanism isn't unique to ovarian tumors; if it works broadly, the market opportunity expands dramatically.
Why This One Is Worth Watching
It's easy to get cynical about incremental cancer approvals. A month here, two months there. But Lifyorli's story is different for three reasons.
First, the mechanism is genuinely novel. This isn't another PD-1 inhibitor or PARP inhibitor. Targeting cortisol-mediated chemoresistance is a new lane in oncology, and the ROSELLA data suggests it works.
Second, the overall survival benefit is real and statistically robust. OS is the gold standard endpoint; many cancer drugs get approved on progression-free survival alone. Lifyorli delivered on both.
Third, it doesn't require biomarker testing. Any eligible patient with platinum-resistant ovarian cancer can receive it. In a field increasingly defined by narrow biomarker-selected populations, a broadly applicable drug fills an enormous gap.
Corcept took a hormone most people associate with stress and job burnout, figured out it was helping tumors survive chemo, and built a drug to stop it. Sometimes the best ideas in medicine come from looking at old biology through a new lens.
Clinical & Regulatory4 min read
The Gene Therapy the FDA Rejected Twice Just Got Approved
The FDA approved Rocket Pharma's gene therapy Kresladi for a rare immune disorder that kills 75% of untreated kids before age two. The twist: the agency had already rejected it twice, and the drug's clinical results were never the problem.
